Vaccine Contract Manufacturing Market Size is valued at USD 2.3 Bn in 2024 and is predicted to reach USD 3.9 Bn by the year 2034 at a 6.0% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
Vaccine contract manufacturing plays a vital role in the pharmaceutical industry, contributing to the efficient and scalable production of vaccines to address various health challenges worldwide. With the expanding efforts in global vaccine distribution, the ability to manage various facets of vaccine manufacturing and logistics positions Contract Manufacturing Organizations (CMOs) to play an important role in ensuring fair access to vaccines worldwide. Consequently, diversifying services becomes a strategic manoeuvre that not only enhances the market presence of CMOs but also contributes to addressing global health challenges. Additionally, advancements in vaccine technology, driven by innovations such as genetic engineering, vaccine delivery technology, and proteomics, continue to shape the industry's dynamic landscape.
Moreover, the increasing implementation of strategic initiatives by key industry players, including activities such as business expansion, partnerships, and acquisitions, also reinforces the projected market growth. The rising global demand for vaccine contract manufacturing is set to propel market expansion.
The global market of vaccine contract manufacturing is segmented on the basis of Vaccine Type, Type of Expression System, Workflow, and Application. The vaccine Type segment is categorised into Attenuated, Inactivated, Subunit-based, Toxoid-based, and DNA-based. By Type of Expression System, the market is segmented into Avian Expression Systems, Bacterial Expression Systems, Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs), Insect Expression Systems, Mammalian Expression Systems, Plant Expression Systems, and Yeast Expression Systems. The Workflow segment consists of Downstream and Upstream. As per the Application segment, the market is divided into Human Use and Veterinary.
Inactivated vaccinations consist of whole bacteria or viruses rendered non-viable or altered to prevent reproduction. Due to the absence of live bacteria or viruses, these vaccines are incapable of transmitting the diseases they are designed to protect against, even in individuals with severely weakened immune systems. This characteristic represents a significant benefit of this vaccine category.
The mammalian category is expected to hold a major share of the global Vaccine Contract Manufacturing market in 2024. The increasing prominence of mammalian cell culture technology has become a notable trend in the vaccine contract manufacturing market. Mammalian cell culture is gaining significance as a preferred method for vaccine production due to its ability to replicate complex biological systems and produce a wide range of proteins. This technology offers advantages such as enhanced yield, scalability, and the ability to produce more complex and effective vaccines. As a result, the rising utilization of mammalian cell culture in vaccine contract manufacturing is shaping the landscape of the market, contributing to its growth and innovation. This trend underscores the industry's ongoing efforts to improve vaccine manufacturing processes and meet the growing demand for safe and effective vaccines.
In recent years, the human-use category has dominated the market with the highest share. The extensive immunization coverage against various diseases in humans has resulted in this sector gaining the leading position in the market.
The North America Vaccine Contract Manufacturing market is expected to register the highest market share. Advantages include a well-established biotechnology and pharmaceutical sectors, a sizable population, and a strong emphasis on healthcare that drives up vaccine demand. The area is a desirable location for contract manufacturing organizations (CMOs) due to its advanced manufacturing infrastructure, highly qualified labour, and well-established regulatory frameworks. Leading vaccine developers and government programs to support vaccine production reinforce North America's leading position in the market and establish it as a main driver of the sector's expansion. In addition, Asia Pacific is estimated to grow at a rapid rate in the global Vaccine Contract Manufacturing market.
The area gains from having highly qualified labourers and sophisticated manufacturing resources. Furthermore, it is a desirable location for vaccine contract manufacturing due to its favourable regulatory conditions and lower labour costs. Hence, Asia-Pacific continues to play a significant role in expanding the global vaccine contract manufacturing market.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 2.3 Bn |
|
Revenue Forecast In 2034 |
USD 3.9 Bn |
|
Growth Rate CAGR |
CAGR of 6.0% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Vaccine Type, By Type of Expression System, By Workflow, By Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Lonza, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Ajinomoto Althea, Inc., Merck KgaA, Cytovance Biologics, Catalent, Inc., IDT Biologika GmbH, Albany Molecular Research, Inc., PRA Health Sciences, ICON plc., Pharmaceutical Product Development, LLC, Cobra Bio, Paragon Bioservices, Inc., Charles River Laboratories, Meridian Life Science (MLS), Eurogentec, GreenPak Biotech, Hong Kong Institute of Biotechnology, WuXi Biologics, Bharat Biotech, Biological E, Others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Vaccine Contract Manufacturing Market Snapshot
Chapter 4. Global Vaccine Contract Manufacturing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter’s Five Forces Analysis
4.6. Competitive Landscape & Market Share Analysis
4.7. Technology Advancement in Vaccine Contract Manufacturing Market
4.8. Key Trends in the Market
Chapter 5. Market Segmentation 1: Vaccine Type Estimates & Trend Analysis
5.1. Vaccine Type & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Vaccine Type:
5.2.1. Avian Expression Systems
5.2.2. Bacterial Expression Systems
5.2.3. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
5.2.4. Insect Expression Systems
5.2.5. Mammalian Expression Systems
5.2.6. Plant Expression Systems
5.2.7. Yeast Expression Systems
Chapter 6. Market Segmentation 2: Type of Expression System Estimates & Trend Analysis
6.1. Type of Expression System & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Type of Expression System:
6.2.1. Attenuated
6.2.2. Inactivated
6.2.3. Subunit-based
6.2.4. Toxoid-based
6.2.5. DNA-based
Chapter 7. Market Segmentation 3: Workflow Estimates & Trend Analysis
7.1. Workflow & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Workflow:
7.2.1. Downstream
7.2.2. Upstream
Chapter 8. Market Segmentation 4: Application Estimates & Trend Analysis
8.1. Application & Market Share, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
8.2.1. Human Use
8.2.2. Veterinary
Chapter 9. Vaccine Contract Manufacturing Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Vaccine Type, 2021-2034
9.1.2. North America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Type of Expression System, 2021-2034
9.1.3. North America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Workflow, 2021-2034
9.1.4. North America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
9.1.5. North America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
9.1.5.1. U.S.
9.1.5.2. Canada
9.2. Europe
9.2.1. Europe Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Vaccine Type, 2021-2034
9.2.2. Europe Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Type of Expression System, 2021-2034
9.2.3. Europe Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Workflow, 2021-2034
9.2.4. Europe Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
9.2.5. Europe Vaccine Contract Manufacturing Market revenue (US$ Million) by country, 2021-2034
9.2.5.1. Germany
9.2.5.2. France
9.2.5.3. Italy
9.2.5.4. Spain
9.2.5.5. UK
9.2.5.6. Rest of Europe
9.3. Asia Pacific
9.3.1. Asia Pacific Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Vaccine Type, 2021-2034
9.3.2. Asia Pacific Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Type of Expression System, 2021-2034
9.3.3. Asia Pacific Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Workflow, 2021-2034
9.3.4. Asia Pacific Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
9.3.5. Asia Pacific Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
9.3.5.1. China
9.3.5.2. India
9.3.5.3. Japan
9.3.5.4. Australia
9.3.5.5. Rest of Asia Pacific
9.4. Latin America
9.4.1. Latin America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Vaccine Type, 2021-2034
9.4.2. Latin America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Type of Expression System, 2021-2034
9.4.3. Latin America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Workflow, 2021-2034
9.4.4. Latin America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
9.4.5. Latin America Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
9.4.5.1. Brazil
9.4.5.2. Rest of Latin America
9.5. MEA
9.5.1. MEA Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Vaccine Type, 2021-2034
9.5.2. MEA Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Type of Expression System, 2021-2034
9.5.3. MEA Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Workflow, 2021-2034
9.5.4. MEA Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
9.5.5. MEA Vaccine Contract Manufacturing Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
9.5.5.1. GCC Countries
9.5.5.2. South Africa
9.5.5.3. Rest of MEA
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Lonza
10.2.2. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
10.2.3. Ajinomoto Althea, Inc.
10.2.4. Merck KgaA
10.2.5. Cytovance Biologics
10.2.6. Catalent, Inc.
10.2.7. IDT Biologika GmbH
10.2.8. Albany Molecular Research, Inc.
10.2.9. PRA Health Sciences
10.2.10. ICON plc.
10.2.11. Pharmaceutical Product Development, LLC
10.2.12. Cobra Bio
10.2.13. Paragon Bioservices, Inc.
10.2.14. Charles River Laboratories
10.2.15. Meridian Life Science (MLS)
10.2.16. Eurogentec
10.2.17. GreenPak Biotech
10.2.18. Hong Kong Institute of Biotechnology
10.2.19. WuXi Biologics
10.2.20. Bharat Biotech
10.2.21. Biological E
10.2.22. Other Prominent Player
Vaccine Contract Manufacturing Market By Vaccine Type
Vaccine Contract Manufacturing Market By Type of Expression System
Vaccine Contract Manufacturing Market By Workflow
Vaccine Contract Manufacturing Market By Application
Vaccine Contract Manufacturing Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
